FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:618-619 February 5, 2004 Number 6 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Schulman, S. PubMed Citation

To the Editor: Schulman et al. (Oct. 30 issue)¹ state that their study of ximelagatran for the secondary prevention of venous thromboembolism was performed "in accordance with the Declaration of Helsinki and Good Clinical Practice." However, 97 patients assigned to the placebo group had a history of recurrent venous thromboembolism, accounting for 16 percent of patients in this group. The current accepted international recommendation for patients with recurrent venous thromboembolism is 12 months of primary oral anticoagulant therapy.² Thus, the assignment of these patients to no therapy is a violation of the Helsinki Declaration. The authors should have studied the . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.